NASDAQ · SEPNHealthcarePharmaceuticals

Septerna financials

$39.13−1.53%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
Revenue$46.0M$1.1M
Gross profit$46.0M$1.1M
Gross margin100.0%100.0%
Operating income-$80.8M-$80.8M
Net income-$48.9M-$71.8M
Net margin−106.4%−6678.9%
Diluted EPS$-1.10$-7.26
EBITDA-$79.2M-$79.4M
Operating cash flow$110.2M-$67.5M
Free cash flow$109.7M-$69.6M
Diluted shares44.3M9.9M

Balance sheet

Period endDec 31Dec 31
Cash & equivalents$120.7M$238.2M
Short-term investments$270.4M$112.7M
Total debt$0.00$0.00
Total assets$596.2M$456.6M
Total liabilities$214.3M$36.5M
Shareholders' equity$381.9M$420.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology